Tricor is owned by Abbvie.
Tricor contains Fenofibrate.
Tricor has a total of 2 drug patents out of which 0 drug patents have expired.
Tricor was authorised for market use on 05 November, 2004.
Tricor is available in tablet;oral dosage forms.
Tricor can be used as adjunctive therapy to diet in adults to reduce ldl-c, triglycerides and apo b, and increase hdl-c in patients with primary hypercholesterolemia or mixed dyslipidemia (types iia, iib) and to treat hypertriglyceridemia (types iv, v).
The generics of Tricor are possible to be released after 21 February, 2023.
Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
---|---|---|---|---|
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US7320802 | ABBVIE | Methods of treatment using nanoparticulate fenofibrate compositions |
Feb, 2023
(18 days from now) | |
US7276249 | ABBVIE | Nanoparticulate fibrate formulations |
Feb, 2023
(18 days from now) |
Drugs and Companies using FENOFIBRATE ingredient
Market Authorisation Date: 05 November, 2004
Treatment: Adjunctive therapy to diet in adults to reduce ldl-c, triglycerides and apo b, and increase hdl-c in patients with primary hypercholesterolemia or mixed dyslipidemia (types iia, iib) and to treat hypertriglyceridemia (types iv, v)
Dosage: TABLET;ORAL
Click on the highlighted region to filter.
900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight
Join them to stay ahead in capturing the next drug going generic